Abo Youssef, N;
Schneider, MP;
Mordasini, L;
Ineichen, BV;
Bachmann, LM;
Chartier-Kastler, E;
Panicker, JN;
(2017)
Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis.
BJU International
, 119
(4)
pp. 515-521.
10.1111/bju.13759.
Preview |
Text
Panicker_Cannabinoids for treating NLUTD in patients with MS_Clean.pdf - Accepted Version Download (210kB) | Preview |
Abstract
OBJECTIVES: To systematically review all available evidence on efficacy and safety of cannabinoids for treating neurogenic lower urinary tract dysfunction (NLUTD) in patients with multiple sclerosis (MS). PATIENTS AND METHODS: The review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Studies were identified by electronic search of Cochrane register, Embase, Medline, Scopus (last search on 11 November 2016). RESULTS: After screening 8469 articles, two randomized controlled trials and one open label study enrolling a total of 426 patients, were included. Cannabinoids relevantly decreased incontinence episodes in all three studies. Pooling data showed mean difference in incontinence episodes per 24 hours to be -0.35 (95% confidence interval -0.46 to -0.24). Mild adverse events were frequent (38-100%), but only two patients (0.7%) reported a serious adverse event. CONCLUSIONS: Preliminary data imply, that cannabinoids might be an effective and safe treatment option for NULTD in patients with MS. However, evidence base is poor and more high-quality, well-designed, adequately powered and sampled studies are urgently needed to reach definitive conclusions. This article is protected by copyright. All rights reserved.
| Type: | Article |
|---|---|
| Title: | Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/bju.13759 |
| Publisher version: | http://doi.org/10.1111/bju.13759 |
| Language: | English |
| Additional information: | © 2017 The Authors BJU International © 2017 BJU International Published by John Wiley & Sons Ltd. This is the peer reviewed version of the following article: Abo Youssef, N; Schneider, MP; Mordasini, L; Ineichen, BV; Bachmann, LM; Chartier-Kastler, E; Panicker, JN; (2017) Cannabinoids for treating neurogenic lower urinary tract dysfunction in patients with multiple sclerosis: a systematic review and meta-analysis. BJU International, which has been published in final form at http://doi.org/10.1111/bju.13759. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. |
| Keywords: | Cannabinoids, meta-analysis, multiple sclerosis (MS), neuro-urology, neurogenic lower urinary tract dysfunction (NLUTD), systematic review |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1542353 |
Archive Staff Only
 |
View Item |
